Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LigBuilder V3: A Multi-Target de novo Drug Design Approach

28 Feb 2020

Abstract excerpt

With the rapid development of systems-based pharmacology and poly-pharmacology, method development for rational design of multi-target drugs has becoming urgent. In this paper, we present the first de novo multi-target drug design program LigBuilder V3, which can be used to design ligands to target multiple receptors, multiple binding sites of one receptor, or various conformations of one receptor. LigBuilder V3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Click Chemistry and Applications
Share to Computational Drug Discovery Methods
Share to HIV/AIDS drug development and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32181242
DOI: 10.3389/fchem.2020.00142

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LigBuilder V3: A Multi-Target de novo Drug Design ApproachPMID 32181242Read ↗

Discovery of Entry Inhibitors for HIV-1 via a New De Novo Protein Design FrameworkSemantic proximity Read ↗

Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico studySemantic proximity Read ↗

A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screeningSemantic proximity Read ↗

Flexible scaffold-based cheminformatics approach for polypharmacological drug designSemantic proximity Read ↗

Structure-Aware Dual-Target Drug Design through Collaborative Learning of Pharmacophore Combination and Molecular SimulationSemantic proximity Read ↗

Exploring the kinase-inhibitor fragment interaction space facilitates the discovery of kinase inhibitor overcoming resistance by mutations.Semantic proximity Read ↗

<i>In silico</i> evolution of protein binders with deep learning models for structure prediction and sequence designSemantic proximity Read ↗

Rational Discovery of Dual-Action Multi-Target Kinase Inhibitor for Precision Anti-Cancer Therapy Using Structural Systems PharmacologySemantic proximity Read ↗

Optimizing the resveratrol fragments for novel in silico hepatocellular carcinoma de novo drug designSemantic proximity Read ↗

Identification of LRRK2 Inhibitors through Computational Drug Repurposing.Semantic proximity Read ↗

Fragment-based Drug Designing to Develop New Hits Against Multiple Receptors of CoronavirusSemantic proximity Read ↗

Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.